Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene
- TONINI G
- BIZZARRI C
- BONFANTI R
- VANELLI M
- CERUTTI F
- FALESCHINI E
- MESCHI, F
- PRISCO F
- CIACCO E
- CAPPA M
- TORELLI C
- CAUVIN V
- TUMINI S
- IAFUSCO, Dario
- BARBETTI F
- EARLY ONSET DIABETES STUDY GROUP OF THE ITALIAN SOCIETY OF PAEDIATRIC
- ENDOCRINOLOGY AND DIABETOLOGY
Publication date
January 2006
DOI Publisher
Springer Science and Business Media LLCAbstract
Activating missense mutations in the gene encoding potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11) represent the most common cause (40 to 64%, depending on populations) of permanent neonatal diabetes mellitus in patients diagnosed in the first 6 months of life [1, 2]. In addition, KCNJ11 activating mutations can lead to transient/relapsing neonatal diabetes
Add to ORKG